Richard Muruve
Founder at ARCH BIOPARTNERS INC.
Net worth: 15 M $ as of 29/04/2024
Network origin in Richard Muruve first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 9 | |
Foccini International, Inc.
Foccini International, Inc. Finance/Rental/LeasingFinance Foccini International, Inc. is an investment company, engages in the product merchandising and advertising design. The company is headquartered in Toronto, Canada.
5
| Extinct | Finance/Rental/Leasing | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Richard Muruve via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
HELIX BIOPHARMA CORP. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member | |
University of Manitoba | College/University | Undergraduate Degree Undergraduate Degree | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
XCPCNL BUSINESS SERVICES CORPORATION | Miscellaneous Commercial Services | Director of Finance/CFO | |
Athyrium Capital Management LP
Athyrium Capital Management LP Investment ManagersFinance Athyrium Capital Management LP (Athyrium) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Jeffrey A. Ferrell in 2008 as Athyrium Capital Management LLC and converted from a Delaware limited liability company to a Delaware limited partnership in 2015. Athyrium provides advisory services on a discretionary basis to its clients, which may include specific tailored vehicles and pooled investment vehicles intended for sophisticated investors and institutional investors. | Investment Managers | Consultant / Advisor | |
Essential Pharmaceuticals LLC
Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Intas Pharmaceuticals Ltd., Essential Pharmaceuticals LLC is a company that manufactures and markets pharmaceutical products. The company is based in Durham, NC. The company was founded in 2006. Emma Jane Johnson has been the CEO of the company since 2023. Essential Pharmaceuticals was acquired by Accord Healthcare, Inc. on July 26, 2017. | Pharmaceuticals: Major | Chairman | |
F2g Inc. | Director/Board Member | ||
AMRYT PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member | |
Essential Pharmaceuticals Ltd.
Essential Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Essential Pharmaceuticals Ltd. manufactures pharmaceutical products. The company was founded on November 24, 2010 and is headquartered in Egham, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Gyrus Capital SA | Investment Managers | Private Equity Investor | |
BiognoSYS AG
BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Packaged Software | Chairman | |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Pharmaceuticals: Major | Chairman | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
CIRCIO HOLDING ASA | Biotechnology | Chairman | |
SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Director/Board Member | |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Other | Chairman | |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman | |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Organon NV
Organon NV Pharmaceuticals: MajorHealth Technology N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Micreos BV
Micreos BV Pharmaceuticals: GenericHealth Technology Micreos BV develops phage-based products against specific dangerous bacteria. It offers human health, food safety, agriculture and animal health products. The company was founded by Mark Offerhaus and is headquartered in Wageningen, the Netherlands. | Pharmaceuticals: Generic | Chairman | |
University of Calgary | College/University | Corporate Officer/Principal | |
Willow Breast & Hereditary Cancer Support | Chairman | ||
McGill University | College/University | Undergraduate Degree | |
The Schulich School of Business | College/University | Masters Business Admin | |
HSBC Securities (Canada), Inc.
HSBC Securities (Canada), Inc. Investment Banks/BrokersFinance HSBC Securities (Canada), Inc. is a full service broker/dealer located in Toronto, Ontario. The firm is a subsidiary of HSBC Holdings Plc (NYSE: HCS, NasdaqGS: HSBA). They are a member of the TMX Group, the Investment Industry Regulatory Organization of Canada (IIROC) and the Canadian Investor Protection Fund (CIPF). The firm offers their clients advisory and execution products and services in the following areas: M&A advisory, equity and debt capital markets, leveraged and acquisition financing, foreign exchange, fixed-income, derivatives and structured products. HSBC Securities specializes in 4 global sectors: financial institutions, consumer/retail Resources, energy and diversified Industries. | Investment Banks/Brokers | Corporate Officer/Principal | |
Bingley Capital, Inc.
Bingley Capital, Inc. Investment ManagersFinance Bingley Capital, Inc. is an Independent Private Equity/Venture Capital firm founded in 2009 by Stephan Bey. Bingley Capital, Inc. is headquartered in Toronto. | Investment Managers | Private Equity Investor | |
First Marathon Securities Ltd.
First Marathon Securities Ltd. Investment Banks/BrokersFinance Part of National Bank of Canada, First Marathon Securities Ltd. is a Canadian company that provides security brokerage and flotation services. The company is based in Toronto, Canada. The company was founded by Eric Savics, Richard S. Hallisey. | Investment Banks/Brokers | Corporate Officer/Principal | |
LIMINAL BIOSCIENCES INC. | Biotechnology | Director/Board Member | |
PTC Therapeutics Ltd.
PTC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2012, PTC Therapeutics Ltd. is a British pharmaceutical company that develops pharmaceutical products. Part of PTC Therapeutics, Inc., the company is based in London, UK. | Pharmaceuticals: Major | Director/Board Member | |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | Corporate Officer/Principal | |
Biogen Canada, Inc. | Corporate Officer/Principal | ||
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Sales & Marketing | |
GENTIUM S.P.A. (ADR) | Pharmaceuticals: Major | Corporate Officer/Principal | |
PTC THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Gentium GmbH | Chief Operating Officer | ||
FENNEC PHARMACEUTICALS INC. | Pharmaceuticals: Major | Chief Operating Officer | |
University of Huddersfield | College/University | Undergraduate Degree | |
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ADVANZ PHARMA CORP. LIMITED | Pharmaceuticals: Major | Director/Board Member | |
ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Chairman | |
University of Toronto | College/University | Graduate Degree | |
ENERGY PLUG TECHNOLOGIES CORP. | Packaged Software | Chief Executive Officer | |
InterUnion Asset Management Ltd
InterUnion Asset Management Ltd Investment ManagersFinance Part of Sancus Lending Group Ltd., InterUnion Asset Management Ltd provides asset management services. The company is based in Toronto, Canada. InterUnion Asset Management was acquired by Asset Management Investment Co. Plc on December 21, 2001 for $6.69 million. | Investment Managers | Director/Board Member |
Statistics
International
Canada | 18 |
United States | 12 |
United Kingdom | 10 |
Switzerland | 7 |
Netherlands | 3 |
Sectoral
Health Technology | 28 |
Finance | 9 |
Consumer Services | 7 |
Commercial Services | 3 |
Technology Services | 3 |
Operational
Director/Board Member | 34 |
Corporate Officer/Principal | 20 |
Chairman | 16 |
Independent Dir/Board Member | 13 |
Director of Finance/CFO | 12 |
Most connected contacts
Insiders | |
---|---|
Patrick Volkert Vink | 30 |
Claude Ayache | 15 |
Adrian Haigh | 15 |
Claude Allary | 10 |
Andrew Bishop | 10 |
Richard Rossman | 5 |
Jerome F. McElroy | 4 |
Conor Gunne | 4 |
Michael Garrity | 4 |
Henry J. Goldberg | 3 |
Daniel Muruve | 3 |
Robert Streda | 2 |
Christian Jagerhofer | 1 |
- Stock Market
- Insiders
- Richard Muruve
- Company connections